IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of STUYVER, et al. Atty. Ref.: 2551-123 10/606,879 Serial No. Group: 1648 Filed: June 24, 2003 Examiner: Peng, Bo For: METHOD FOR TYPING AND DETECTING HBV Commissioner for Patents June 14, 2007 P.O. Box 1450 Alexandria, VA 22313-1450 Sir: INFORMATION DISCLOSURE STATEMENT 1. PTO-1449 Pursuant to 37 CFR 1.97(b) [within 3 months of filing or prior to 1st Office Action on the merits] N/C 2.(a) Statement Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] N/C \boxtimes 2 .(b) Fee Payment Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] \$180.00 3. Pursuant to 37 CFR 1.97(d)

[after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]

06/15/2007 MAHMED1 00000123 10606879 01 FC:1806 180.00 OP

\$180.00

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

4. A list of documents on Form PTO-1449 is enclosed herewith. Copies of the listed "Other Documents" and WO 97/40193 and WO 94/26904 are being filed electronically with PTO PAIR. The listed other documents and WO applications, other than the noted claims and File Histories, are contained in the file history of Serial No. 10/453,792, where the documents are of record.
This paper is submitted in accordance with:

	5.	37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]					
\boxtimes	6.	37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier and					
		a) The required Statement made in item 8 below; or					
	\boxtimes	b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.					
	7.	37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and					
		 The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and 					
		b) The required Statement is stated in item 8 below.					
	8.	Statement under 37 CFR 1.97(e)					
		a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or					

b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37

 Information Disclosure Statement June 14, 2007

CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted, NIXON & VANDERHYE P.C.

By: /B. J. Sadoff/
B. J. Sadoff
Reg. No. 36,663

901 North Glebe Road, 11th Floor

Arlington, VA 22203-1808 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

Of 3

INFORMATION DISCLOSURE

SERIAL NO.

(C	ı	Т	Δ	T	l	O	N	
-	_			,			$\boldsymbol{\smile}$		

iidi Oidiv	CITATION	2551 APPLIC		10/606,879			
(llee	accord abouts if accordant	STU'	YVER, et al.				
(Use s	several sheets if necessary)			ROUP			
				648			
*EXAMINER	· · · · · · · · · · · · · · · · · · ·	0.8	S. PATENT DOCUMENTS			EII ING	DATE
INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	IF APPR	
	US 2004-0029110 A1	2-2004	Stuyver et al				
	6,709,812	3-2004	Stuyver et al				
	6,555,311	04/2003	Locarnini				
	2005-0175990	08/2005	Stuyver				
						<u> </u>	
		FOR	EIGN PATENT DOCUMENTS				
	2001115117						LATION
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
	97/40193	10/1997	WO				
	94/26904	11/1994	WO				
					L		<u> </u>
	OTHER DOCUM	ENTS (inc	cluding Author, Title, Date, Pe	ertinent pa	ages, etc.	<u>) </u>	
	File History (FH) of U.S. application Serial No. 09/155,885 retrieved from USPTO IFW June 14, 2007						
	File History (FH) of U.S. application Serial No. 10/453,792 retrieved from USPTO IFW June 14, 2007						
			328 filed May 22, 2007				
			Met al, pp 575-9, "Hepatitis B virus gel ned FH of Serial No. 10/453,792	nes and thei	r expressior	n in <i>E. C</i>	oli"
	Nucleic Acids Research(1983), vol. 11(6), ONO Y et al, pp 1747-57, "The complete nucleotide of the cloned hepatitis B virus DNA; subtype adr and adw" Figure 2 and 3. copy contained in attached FH of Serial No. 10/453,792						
	J. General Virology (1988), vol. 69, VAUDIN M et al, pp 1383-9, "The complete nucleotide sequence of the genome of a hepatitis B virus isolated from a naturally infected chimpanzee" Figure 1. copy contained in attached FH of Serial No. 10/453,792						
	J. General Virology (1988), vol 69, OKAMOTO F et al, pp. 2575-83, "Typing hepatitis B virsu by homology in nucleotide sequence: comparison of surface antigen subtypes" Figure 1. copy contained in attached FH of Serial No. 10/453,792						
	and human flanking re FH of Serial No. 10/45	egions in the	l et al, pp. 285-96, "Nucleotide sequer e genome of the PLC/PRF/5 cell line"	Figure 5. co	py containe	d in atta	ched
	strains of diverse geog	graphical or	l, NORDER H <i>et al</i> , pp 1341-8, "Gene igin and natural variations in the prima hed FH of Serial No. 10/453,792	tic relatedne ary structure	ss of hepat of the surfa	itis B vira ce antig	al en"
xaminer			Date Considered	1			
			Date considered	·			

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.

2551-123 **APPLICANT**

JUN 1 4 2007

SERIAL NO.

10/606.879

(Use several sheets if necessary)

STATE TRAB STUYVER, et al. **FILING DATE**

GROUP

June 24, 2003

1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL

DOCUMENT NUMBER

FILING DATE IF APPROPRIATE

YES

CLASS

TRANSLATION

DOCUMENT

No. 10/453,792

*Examiner

DATE

COUNTRY

CLASS

SUBCLASS

SUBCLASS

NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

FOREIGN PATENT DOCUMENTS

J Medical Virology (1994), vol. 44(1), HORIKITA M et al, pp 96-103, "Differences in the entire nucleotide sequence between hepatitis B virus genomes from carriers positive for antibody to hepatitis B e antigen with and without active disease" Table IV. copy contained in attached FH of Serial No. 10/453,792 GenBank Accession No. D50489, "Hepatitis B virus DNA, complete genome" (no date available), copy contained in attached FH of Serial No. 10/453,792 J General Virology (1995), vol. 45, UCHIDA T et al, pp 247-52, "Complete nucleotide sequences and the characteristics of two hepatitis B virus mutants causing serologically negtive acute or chronic hepatitis B: Page 249. copy contained in attached FH of Serial No. 10/453,792 J General Virology (1996), vol. 3, ALEXOPOULOU A et al, pp 173-81, "Whole genome analysis of hepatitis B virus from four cases of fulminant hepatitis: genetic variability and its potential role in disease pathogenicity" Table 3. copy contained in attached FH of Serial No. 10/453,792 J General Virology (1997), vol. 78, BOWYER S et al, pp 1719-29, "A unique segment of the hepatitis B virus group A genotype identified in isolates from South Africa" Figure 5 copy contained in attached FH of Serial No. 10/453,792 Carman et al, "Vaccine-induced escape mutant ...", The Lancet, Vol. 336, 1990 (8711) pages 325-329. copy contained in attached FH of Serial No. 10/453,792
Fujii et al, "Gly¹⁴⁵ to Arg Substitution in HBs Antigen of ...", Biochemical and Biophysical Research Communications, Vol. 184, No. 3, May 15, 1992, pages 1152-1157. copy contained in attached FH of Serial No. 10/453,792 Yamamoto et al, "Naturally Ocurring Escape Mutants of Hepatitis B Virus with ...", Journal of Virology, Vol. 68, No. 4, April, 1994, pages 2671-2676. copy contained in attached FH of Serial No. 10/453,792 Carman, "The clinical significance of surface antigen variants ...", Journal of Viral Hepatitis, 1997, 4 (Suppl. 1) 11-20. copy contained in attached FH of Serial No. 10/453,792 Wang GT et al, Chung Hua I Hseuh Tsa Chih, "Sequencing of hepatitis B Virus DNA fragment coding major HBsAg of escape mutant", 1994 June 74(6) pages 355-357, 391 (PubMed English Abstract PMID 7994645) copy contained in attached FH of Serial No. 10/453,792 Ren H et al, Chung Hua I Hseuh Tsa Chih, "Expression of 12 antibody escape mutants of hepatitis B virus surface antigen gene in mammalian cell by using an Epstein-Barr based vector", 1995 75(7) pages 396-398 (PubMed English Abstract PMID 7553156). copy contained in attached FH of Serial No. 10/453,792 Chenault, "Patterns of nucleotide sequence variation among cauliflower mosaic virus isolates", (Biochimie 76:3-8, 1994) copy contained in attached FH of Serial No. 10/453,792 Fischer, "Generation of Duck Hepatitis B Virus Polymerase Mutants through Site-Directed Mutagenesis....", (Antimicrobial Agents and Chemotherapy 40(8): 1957-1960, August 7, 1996 copy contained in attached FH of Serial No. 10/453,792

Norder, "Complete Genomes, Phylogenetic Relatedness, and Structural Proteins of Six Strains of the Hepatitis B Virus. Four of Which Represent Two New Genotypes", (Virology 198: 489-503, 1994). copy contained in attached FH of Serial

Delaney et al, "Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation", Antiviral Chemistry & Chemotherapy 12:1-35 (2001). copy contained in attached FH of Serial No. 10/453,792

Date Considered

Aye et al, "Hepatitis B virus polymerase mutations Famciclovir therapy in patients following liver transplantation", Hepatology Vol. 24, No. 4, Pt.2, September 1996. copy contained in attached FH of Serial No. 10/453,792

Bartholomew, "Hepatitis-B-Virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation".

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

(Lancet 349: 20-22, January 1997). copy contained in attached FH of Serial No. 10/453,792

Form PTO-FB-A820 (Also PTO-1449)

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)